相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types
X. Zhao et al.
ANNALS OF ONCOLOGY (2020)
Testing for COVID-19 in lung cancer patients
A. Passaro et al.
ANNALS OF ONCOLOGY (2020)
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation
Mallika Lala et al.
EUROPEAN JOURNAL OF CANCER (2020)
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement q
Matthias Guckenberger et al.
RADIOTHERAPY AND ONCOLOGY (2020)
COVID-19: impact on cancer workforce and delivery of care
Susan Mayor
LANCET ONCOLOGY (2020)
Cancer guidelines during the COVID-19 pandemic
Talha Khan Burki
LANCET ONCOLOGY (2020)
Challenges in lung cancer therapy during the COVID-19 pandemic
Luana Calabro et al.
LANCET RESPIRATORY MEDICINE (2020)
The Multidisciplinary Team (MDT) Approach and Quality of Care
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2020)
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
Timothy P. Hanna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19
Mark A. Lewis
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Fair Allocation of Scarce Medical Resources in the Time of Covid-19
Ezekiel J. Emanuel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic
Paolo Tarantino et al.
EUROPEAN JOURNAL OF CANCER (2020)
Effect of the COVID-19 pandemic on cancer treatment and research
Kamal S. Saini et al.
LANCET HAEMATOLOGY (2020)
Caring for patients with cancer in the COVID-19 era (vol 26, pg 665, 2020)
Joris van de Haar et al.
NATURE MEDICINE (2020)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Celeste Lebbe et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
How we treat patients with lung cancer during the SARS-CoV-2 pandemic:primum non nocere
Giuseppe Banna et al.
ESMO OPEN (2019)
CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC.
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer
G. V. Long et al.
ANNALS OF ONCOLOGY (2018)
Management of Malignant Pleural Effusions An Official ATS/STS/STR Clinical Practice Guideline
David J. Feller-Kopman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
1232PModel-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types
X Zhao et al.
ANNALS OF ONCOLOGY (2018)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus et al.
ANNALS OF ONCOLOGY (2017)
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J. Klastersky et al.
ANNALS OF ONCOLOGY (2016)
Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT - the Nordic experience
Karin Lindberg et al.
ACTA ONCOLOGICA (2015)
Patterns of Disease Recurrence after SABR for Early Stage Non-Small-Cell Lung Cancer Optimizing Follow-Up Schedules for Salvage Therapy
Naomi E. Verstegen et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic Bronchoscopy Improves Spirometry, Quality of Life, and Survival in Central Airway Obstruction
Kamran Mahmood et al.
RESPIRATION (2015)
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2006)
分享论文
